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Small-cell lung cancer (SCLC) is a highly aggressive malignancy
and most patients have widespread disease at the time of diag-
nosis. Though the disease is usually chemo- and radiosensitive
initially, responses to treatment are normally not lasting even in
cases of limited disease. Moreover, since autologous bone marrow
(BM) or peripheral blood progenitor cell transplantation of SCLC
patients may represent an additional therapeutic option, sensitive
and reproducible methods for detecting even minimal contamina-
tion levels by tumour cells are needed. A growing body of
evidence suggests that not only BM contamination by SCLC cells
is far more frequent than previously shown by traditional
cytohistological methods (Stahel et al, 1985; Leonard et al, 1990;
Pasini et al, 1994b, 1995) but also that BM involvement may have
clinical relevance (Leonard et al, 1990; Bucher et al, 1994; Pasini
et al, 1994b, 1995). Immunocytochemistry is a convenient method
for detecting BM micrometastases thanks to its simplicity, relia-
bility and relative low cost (Leonard et al, 1990; Molino et al,
1991; Beiske et al, 1992; Skov et al, 1992; Pasini et al, 1994a),
whereas other techniques, such as in vitro cultures of marrow cells
(Pollard et al, 1981; Hunter et al, 1987; Everard et al, 1990) or
magnetic resonance imaging (Trillet et al, 1989), are cumbersome,
time-consuming and expensive.
Among the SCLC-related antigens, the neural cell adhesion
molecule (NCAM, CD56, NKH-1) is recognized by the cluster-1
monoclonal antibodies (Hirsch and Hansen, 1980; Kelly et al,
1984; Stahel et al, 1994). NCAM belongs to a family of
membrane-bound, homophilic calcium-dependent glycoproteins
involved in both cell–cell and cell–substrate interactions
(Keilhauer et al, 1985; Cunningham et al, 1987; Rutishauer et al,
1988; Acheson et al, 1991). They are also expressed in a wide
variety of normal tissues, mainly of neural and mesenchymal
lineage (Cunningham et al, 1987; Dalseg et al, 1989; Patel et al,
1991; Lanier et al, 1992), as well as in most neuroectodermal and
some mesodermal tumours (Patel et al, 1989, 1991; Moolenaar et
al, 1990; Tome et al, 1991; Kern et al, 1992; Miettinen and Cupo,
1993; Ledermann et al, 1994; Pasini et al, 1994a, 1995; Nakamura
et al, 1995). Several isoforms of the molecule have been described
that derive from a single copy gene by alternative mRNA splicing
(Cunningham et al, 1987). The expression of these isoforms is
regulated, depending on developmental stage and in a tissue-
specific manner. During embryogenesis, strongly sialylated
isoforms of 200–250 kDa are prevalent (embryonic type), while
the less sialylated isoforms of 185, 145 and 129 kDa are found in
adult tissues (Pollerberg et al, 1986). The isoforms of NCAM
expressed by SCLC are mostly embryonic (Moolenaar et al, 1990;
Komminoth et al, 1991; Patriarca et al, 1997). Although the
biological significance of these molecules in SCLC is unknown,
there is some evidence that sialylated isoforms are involved in the
metastatic process owing to their reduced adhesive properties
(Doyle et al, 1990; Moolenaar et al, 1990, 1992; Carbone et al,
1991; Komminoth et al, 1991; Patriarca et al, 1997).
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Summary Recent reports have suggested that tumour cell immunodetection in bone marrow of small-cell lung cancer patients is by far more
frequent than found cytohistologically and may have clinical relevance. This study evaluates primarily the efficacy of chemotherapy as method
of in vivo purging, but also the relationship of marrow involvement with survival. A total of 112 bone marrow aspirates from 30 chemo-naïve
patients were stained twice using anti-NCAM antibodies, first at diagnosis and then after chemotherapy (24 patients) or at disease
progression (six patients). Marrow contamination was associated with lower survival (P = 0.002), and was also detected in 7/17 patients
conventionally staged as having limited disease. At multivariate analysis, marrow involvement was an independent factor of unfavourable
prognosis (P = 0.033). The amount of tumour contamination, before and after chemotherapy, remained unchanged also in responders and
even in the subset of patients with apparent limited disease. Following chemotherapy, bone marrow became tumour negative only in 25% of
initially positive responders and in none of non-responders. Our results indicate that (i) chemotherapy is not effective in purging bone marrow
even in chemo-responsive patients and (ii) a subset of patients with limited disease and negative bone marrow aspirates might have a more
favourable prognosis. © 1999 Cancer Research Campaign
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Correspondence to: G PelosiStaging procedures for primary or recurrent SCLC generally
include clinical history, physical examination, chest X-ray, total
body computerized tomography (CT) scan, and laboratory find-
ings (Abrams et al, 1988; Perez et al, 1997). Moreover, most
staging protocols include BM assessment through morphological
screening of mono- or bilateral core biopsies, aspiration clots or
smears from iliac crests (Abrams et al, 1998). Many studies have
addressed the detection of SCLC cells in bone marrow aspirates
(BMA) by immunocytochemistry (Frew et al, 1986; Berendsen et
al, 1988; Hay et al, 1988; Moss et al, 1988; Trillet et al, 1989;
Leonard et al, 1990; Beiske et al, 1992; Skov et al, 1992;
Myklebust et al, 1993a, 1993b), but the clinical relevance of this
approach is still debated. Furthermore, few reports have investi-
gated the relationship between BM involvement and prognosis
(Leonard et al, 1990; Bucher et al, 1994; Pasini et al, 1994b, 1995,
1998), but no study has systematically assessed the effects of treat-
ment on marrow contamination in sequential BMA. Only two
papers reported earlier systemic relapse in patients with immuno-
cytological positive BM at re-staging after chemotherapy (Hay et
al, 1988) or the disappearance of bone marrow contamination after
induction chemotherapy (Menard et al, 1988).
In this study we used immunocytochemistry to (i) assess
marrow involvement in 30 chemo-naïve patients with SCLC in
two sequential BMA, one taken at diagnosis and the other either
after chemotherapy or during disease progression; (ii) evaluate the
efficacy of chemotherapy in BM purging; (iii) correlate these find-
ings with clinicopathological features. Our findings suggest that
the presence and the extent of BM involvement parallel the clin-
ical aggressiveness of the disease, and that chemotherapy seems 
ineffective in purging BM.
MATERIALS AND METHODS
Patients, staging and treatment
From our series of BMA from 119 chemo-naïve SCLC patients
collected at the Divisione Clinicizzata di Oncologia Medica of the
University of Verona between March 1990 and May 1997 we
chose 30 patients. The selection criteria included: (i) the avail-
ability of enough unstained cytospin obtained from two consecu-
tive BMA in the same patient, one at the time of diagnosis and the
other at restaging; and (ii) the presence in each cytospin of a high
cellularity composed of well-preserved and monolayered mono-
nuclear cells. In fact, only the use of high-quality cytospins
containing at least 1 ´ 105 mononuclear cells per patient allowed
quantitative estimation of tumour cells to be performed with
reasonable confidence.
The clinical and pathological data of the 30 patients are summa-
rized in Table 1. The diagnosis of SCLC was made on trans-
bronchial biopsies (22 cases), fine needle aspiration biopsies
(three cases), surgically excised lungs (three cases) and lymph
node biopsies (two cases). All patients were staged by evaluating
clinical history, physical examination, chest X-ray, total body CT
scan, haemogram, routine laboratory profile and bilateral BM
biopsies. BM aspirations were performed after marrow biopsy,
stored and not evaluated for staging purposes. At diagnosis
patients were classified as having limited disease (LD, 17 cases) if
tumour was restricted to one hemithorax with regional metastases
to hilar, ipsilateral or contralateral mediastinal, supraclavicular
lymph nodes and/or with ipsilateral pleural effusion. By definition,
BM biopsies in these cases were negative. Extensive disease (ED,
13 cases) was diagnosed if tumour extended beyond these sites.
At restaging, disease status was assessed according to standard
criteria as follows: complete remission (CR), partial remission
(PR), stable disease (SD) and progressive disease (PD). Near
complete remission (NCR) was defined as partial remission
greater than 90%.
The first BMA was always obtained at diagnosis before starting
chemotherapy. The second sample was taken in 24 patients after
completion or at least after three cycles of chemotherapy and in six
at disease progression far from chemotherapy. Nineteen patients
were treated with CAVE (cyclophosphamide, doxorubicin,
vincristine and etoposide), six with HD-ICE (high-dose ifos-
famide, carboplatinum and etoposide), three with cisplatinum and
etoposide, and two with single-agent etoposide or teniposide. In
the analysis of the effects of chemotherapy, we have grouped
together CR, NCR and PR as the responder group, and SD and PD
as the non-responder group. The six patients assessed later at
disease progression were not considered for response to treatment.
Immunocytochemical procedures
Diagnostic material consisted of 112 BMA (3–5 ml each) obtained
from posterior iliac crests. All patients were analysed twice, with
bilateral aspirates in 26 (104 samples) and unilateral in four (eight
samples). These samples were sedimented onto a Ficoll-Hypaque
(Pharmacia, Uppsala, Sweden) density gradient at 400 g for
30 min at 19°C. The mononuclear cell layer was washed three
times in RPMI-1640 (MA Bioproducts, Walkersville, MD, USA)
supplemented with 15% heat-inactivated fetal calf serum (FCS;
350 g for 7 min at 4°C), and then resuspended at 1–1.5 ´ 106 cells
ml–1. One hundred microlitres of this cell suspension were
cytospun (Cytospin 3®, Shandon Scientific Limited, Cheshire,
England) using 500 rpm for 4 min at room temperature. This
procedure gave a monolayered spot of 0.6 cm in diameter,
composed of 50–75 ´ 103 well-preserved mononuclear cells for
each slide. The slides were fixed in cold acetone for 5 min.
The tumour cells were characterized by the expression of
NCAM using two antibodies, clone NCC-LU243 (IgG2a) and
NCC-LU-246 (IgG1) (Nippon Kayaku Co, Tokyo, Japan). The
specificity of the two antibodies was reported with adjacent
epitopes of the 145- and 185-kDa-human isoforms of NCAM
(Hirano et al, 1989; Moolenaar et al, 1990), as well as of the highly
sialylated isoforms (Moolenaar et al, 1990). Immunostaining
procedure was derived from Davidoff’s ‘sandwich’ method
(Davidoff et al, 1991) with minor modifications. Briefly, after
primary antibody incubation (20 ml ml–1 for 1 h), biotinylated
horse anti-mouse antibody (3 mg ml–1 for 30 min; Vector
Laboratories, Burlingame, CA, USA), alkaline phosphatase–anti-
alkaline phosphatase mouse complex (20 mg ml–1 for 30 min;
Dakopatts, Glostrup, Denmark), again biotinylated horse anti-
mouse antibody, and streptavidin alkaline phosphatase complex
(3 mg/ml for 30 min; Southern Biotechnology Associates,
Birmingham, AL) were added in sequence. Blocking of endoge-
nous alkaline phosphatase activity and development of alkaline
phosphatase activity of immunocomplexes were performed as
previously described in detail (Pelosi et al, 1997). Slides were
lightly counterstained with 1% Harris haematoxylin. The speci-
ficity of all reactions was verified by replacing primary antibodies
with unrelated mouse IgG in buffer at a comparable dilution.
1214 G Pelosi et al
British Journal of Cancer (1999) 81(7), 1213–1221 © 1999 Cancer Research CampaignCytospins of N592 cell line stained in parallel were employed as
external positive control, whereas mononuclear cells of each BMA
were used as internal negative control. Moreover, BMA from
healthy volunteers and patients with unrelated, non-malignant
diseases provided the control group for non-carcinoma patients. In
a set of experiments we used BMA from healthy volunteers and
from patients with unrelated, non-malignant diseases artificially
contaminated with a known number of tumour cells at different
dilutions in order to assess the sensitivity of our immunocyto-
chemical method in the detection of NCAM-reactive tumour cells
as described elsewhere (Pelosi et al, 1999). Results of these artifi-
cial contamination tests showed that NCAM-positive tumour cells
were detected in expected quantities in all mixtures up to the final
dilution of 1/105 bone marrow cells (data not shown). Double
immunostains for NCAM and low molecular weight cytokeratins
were carried out in both BMA and artificial mixtures to differen-
tiate, in doubtful cases, true tumour epithelial cells from other
NCAM-positive non-tumour cells, including natural killer (NK)
cells, as described elsewhere (Pelosi et al, 1999).
Evaluation and scoring criteria of immunostained SCLC
cells
All counts of labelled cells were performed independently and
blindly by two observers (GP and FP) at a magnification of ´400,
without knowledge of patient identity or stage of disease. Cells reac-
tive for NCAM were considered neoplastic if a continuous and thick
ring of staining was apparent throughout the cell membrane, and the
cell morphology was consistent with that of epithelial tumour cells.
Although CD56 is expressed in the BM also by some lymphoid cells
including NK cells, the NCAM membrane and intensity pattern is
considerably different between tumour and lymphoid cells (see
Results). In every patient, two to four slides were examined for each
antibody and for each time point. The number of NCAM-reactive
tumour cells among 105 mononuclear cells was assessed by each
observer for each antibody by counting every case twice: the higher
score for each antibody and the higher score between the two
observers were thus reported. Immunoreactivity for cytokeratins
resulted in a strong labelling of the cell cytoplasm.
Immunodetection of bone marrow micrometastases in SCLC patients 1215
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Table 1 Clinicopathological data
BMAc Metastasis localizationd
Relation to Disease Survival
Patient no. Age/sex Diagnosisa Stageb 1st 2nd Li AG B BMB LN CNS treatmente statusf (months)
1 61/M TBB LD – – – – – – – – ACT CR 53+
2 53/M LuFNAC LD – + – – – – – – ACT CR 15
3 56/M Lu LD + + – – – – – – ACT CR 15
4 47/F Lu LD – – – – – – – – ACT CR 54+
5 65/M TBB LD – – – – – – – – ACT CR 42+
6 58/M TBB LD + + – – – – – – ACT NCR 19
7 48/F TBB LD – – – – – – – – ACT NCR 16
8 60/M TBB LD – – – – – – – – ACT NCR 16
9 60/M TBB LD – – – – – – – – ACT PR 17
10 74/M TBB ED + + – – – + +(M) – ACT PR 11
11 57/M TBB ED + – + – + + – – ACT PR 9
12 61/M TBB LD + + – – – – – – ACT PR 18
13 67/M TBB ED + + – – + + +(M) – ACT SD 9
14 58/M TBB ED + + – – – – +(S) – ACT SD 9+
15 62/M Lu LD – + – – – – – – ACT PD 5+
16 59/M TBB ED + + + – – + +(M) – ACT PD 5
17 65/M TBB LD + + – – – – – – ACT PD 11
18 66/F LNB ED + – – – – – +(MA)– DCT PR 9
19 58/M TBB ED + + + – – + – – DCT PR 6
20 55/M LuFNAC ED + + – + – – +(M) + DCT SD 9
21 61/M LiFNAC ED + + + – + + – – DCT SD 9
22 66/F TBB ED + + + – – – – + DCT PD 4
23 42/F TBB ED – + – – – – +(S) – DCT PD 5
24 62/M LNB ED + + + – – + +(A) – DCT PD 9
25 54/M TBB LD + + – – – – – – FFCT PD 10
26 59/M TBB LD + + – – – – – – FFCT PD 17
27 48/M TBB LD – + – – – – – – FFCT PD 30
28 42/M TBB ED + + – – + – +(M) + FFCT PD 10
29 50/M TBB LD + + – – – – – – FFCT PD 9
30 68/M TBB LD – + – – – – – – FFCT PD 10+
aTBB, trans-bronchial biopsy; LNB, lymph node biopsy; LuFNAC, lung fine needle aspiration cytology; Lu, surgically excised lung; LiFNAC, liver fine needle
aspiration cytology. bStage of disease at diagnosis: LD, limited disease; ED, extensive disease. cBMA, reactivity of bone marrow aspirates for tumour cells: –,
negative; +, positive. dMetastasis distribution at diagnosis: –, absent; +, present; Li, liver; AG, adrenal gland; B, skeletal bone; BMB, bone marrow biopsy; LN,
lymph nodes (S=supraclavicular; M=mediastinal; MA=mediastinal and abdominal; A=abdominal); CNS, central nervous system. eRelationship between the 2nd
BMA and the treatment: ACT, after chemotherapy; DCT, during chemotherapy; FFCT, far from chemotherpy. fDisease status was evaluated on the occasion of
the second BMA. CR, complete remission; NCR, near complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.Statistical analysis
The statistical tests used were Mann–Whitney’s test and Fisher’s
exact t-test. The intra- and interobserver reproducibility was evalu-
ated by analysis of variance and Spearman’s rank test respectively.
Survival curves were calculated with Kaplan–Meier’s method
(Kaplan and Meier, 1958) and compared by the log-rank test
(Mantel and Haenszel, 1959). Multivariate analysis was carried out
by means of the proportional hazards Cox-model (Cox, 1972). The
following variables were examined: stage of disease (patients with
LD and negative BMA vs patients with LD and positive BMA vs
patients with ED); BMA contamination after chemotherapy (nega-
tive vs positive); disease status (responders vs non-responders);
age; and sex. In all tests, P-value was considered as significant at
the ≤ 0.05 level. All significance levels were of the two-sided type.
RESULTS
Tumour cells in bone marrow were highlit by a strong membrane
labelling and could be seen not only as individual cells but also as
aggregates of various sizes. Both individual and clustered tumour
cells were generally larger than normal mononuclear cells. Control
experiments showed that normal bone marrow elements on
cytospin preparations of both clinical material and control group
of non-cancer patients were completely negative for NCAM,
although a few lymphoid cells showed a weak and discontinuous
ring of staining along the cell membrane. Results of double
immunostaining for NCAM and cytokeratins confirmed a definite
colocalization of the two markers in the same cells. These features
are illustrated in Figure 1 A–C.
In our series, 17 patients had limited disease, and 13 extensive
disease. The results of quantitative estimations of marrow
contamination, clinical and pathological correlations, and survival
analysis are summarized in Tables 2–7.
There was no significant difference in the number of NCAM-
reactive tumour cells between the two antibodies, and the cases of
positive and negative BMA were identical for both antibodies.
Moreover, no differences were found in the distribution of tumour
cells between the two aspiration sites. Overall, BMA were positive
in 19/30 (63%) patients at onset and in 22/30 (73%) at re-staging.
The order of magnitude of BM involvement at diagnosis and re-
staging is reported in Table 2. The wide range of tumour cells was
due to two patients (no. 19 and no. 29) who showed a high level of
bone marrow contamination at diagnosis and at progression
respectively. Intraobserver reproducibility did not show statisti-
cally significant differences in the estimated number of tumour
cells, and a high grade of correlation between the two observers
was found (P < 0.001, 95% confidence interval (CI) 98–100%).
Overall positivity of BMA at diagnosis was significantly associ-
ated only with extensive disease (P = 0.005), liver metastases (P =
0.045) and positive conventional BM biopsy (P = 0.025) (Table 3).
At diagnosis, the 17 patients with LD showed a mean level of
BM involvement lower than that found in the 13 patients with ED
(116 vs 1590 cells, P = 0.008) (Table 4). However, in the LD
patients there was a prevalence of negative marrow specimens
(58.8%) compared to ED patients (7.7%). The level of contamina-
tion in the LD patients with positive BMA, though apparently
lower, did not differ statistically from that of ED patients (281 vs
1590 cells respectively). The difference remained not significant
even after exclusion of responsive patient who showed the highest
level of bone marrow contamination at diagnosis (not shown).
At the time of re-staging, marrow infiltration in LD patients,
compared with that of the first aspirate, remained unchanged in
ten patients showing remission of disease (53 vs 62 cells), and
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Figure 1 (A) Individual and clustered small cell lung cancer cells in the
bone marrow highlit by a strong labelling for NCAM along the entire cell
membrane, and with a cell morphology consistent with that of tumour cells;
normal mononuclear cells are unstained (3 400, bar = 50 mm); (B) Rarely,
lymphoid cells showed a weak and discontinuous ring of decoration for
NCAM along the cell membrane (3 1000, bar = 15 mm); (C) Double staining
for NCAM and low molecular weight cytokeratins showing a definite
colocalization of the two markers in the same cell: cytokeratins (red) and
NCAM (blue-black) (3 1000, bar = 8 mm)increased in seven with progressive disease (205 vs 3968 cells,
P = 0.026). In ED patients, there were no significant differences
between the two aspirates, though the number of tumour cells was
lower in the four patients achieving partial response (Table 4). This
cohort of patients, however, is too small to be analysed separately.
The relationship between treatment and BMA involvement was
assessed for the 24 patients (from patient 1 to patient 24, Table 1),
who were restaged after completion or after at least three cycles of
chemotherapy. Of these, 14 were responders (five CR, three NCR,
six PR) and ten non-responders (four SD and six PD) (Table 5).
In the group of the 14 responders, the number of contaminating
cells did not significantly change between the first and the second
aspirate, though there was a reduction of the mean marrow conta-
mination (746 vs 124 cells) (Table 4). The difference remained not
Immunodetection of bone marrow micrometastases in SCLC patients 1217
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Table 2 NCC-LU-243 and NCC-LU-246 reactivities as a function of the time point of BMA
NCC-LU-246 NCC-LU-243
Tumour cellsa Tumour cellsa
Time point Positive cases Mean ± s.d. Range Mean ± s.d. Range
At diagnosis (1st BMA) 19/30 1061 ± 2230 10–9418 1175 ± 2276 15–9750
At re-staging (2nd BMA) 22/30 1739 ± 4499 10–20 000 1873 ± 4389 30–20 000
aNumber of NCAM-reactive tumour cells among 100 000 mononuclear cells.
Table 3 Characteristics of the patients in relation to BM involvement
Variable Category BMA Cases % BMA-positive P-value
Stage LD 1st 17 41.2
ED 1st 13 92.3 0.005
Liver metastases Present 1st 6 100
Absent 1st 24 54.2 0.045
BM biopsy Positive 1st 7 100
Negative 1st 23 52.2 0.025
Disease status Respondersa 2nd 14 42.8
Non-respondersa 2nd 10 100 0.004
Sex Male 1st 25 68
Female 1st 5 40 NS
Age (median value) ≤59 years 1st 16 68.7
>59 years 1st 14 57.1 NS
aTen of the 14 responders had LD and eight of the ten non-responders had ED (P = 0.036).
Table 4 Number of tumour cells in BMA as a function of stage, disease evolution and treatment
BMA at diagnosis BMA at re-staging
No. of cases Mean ± s.d. Median Mean ± s.d. Median P-value
Stage Limited disease 17 116 ± 253 0 – – 0.008
Extensive disease 13 1590 ± 2675 204 – –
Evolution LD with progressive disease 7 205 ± 372 32 3968 ± 7306 363 0.026
LD with disease remission 10 53 ± 104 0 62 ± 94 0 NS
ED with progressive disease 9 1195 ± 1459 58 1300 ± 2091 167 NS
ED with partial response 4 2477 ± 4628 238 277 ± 450 82 NS
Treatment Responders 14 746 ± 2498 8 124 ± 251a 0N S
Non-responders 10 909 ± 1444 45 1229 ± 1982a 220 NS
aP = 0.006.
Table 5 Results of BMA in relation to stage and time point of evaluation
At diagnosis At re-staging
Patients Stage No. +/– +/–
All patients LD 17 7/10 11/6
ED 13 12/1 11/2
Total 30 19/11 22/8
Responders LD 10 3/7 4/6
ED 4 4/0 2/2
Total 14 7/7 6/8
Non-responders LD 2 1/1 2/0
ED 8 7/1 8/0
Total 10 8/2 10/0significant even excluding the responsive patient who showed the
highest level of contamination at diagnosis (not shown). Ten of
these patients at diagnosis had LD, with seven of them showing
also a negative BMA (P = 0.036) (Tables 3 and 5). Among respon-
ders, the second aspirate became positive in one of the seven nega-
tive LD patients and negative in two of the four ED patients, while
in one patient there was an increase in the number of contami-
nating cells (Tables 1 and 5 and Figure 2). Even in the non-
responder patients, the level of contamination was not different
between the first and the second aspirate (909 vs 1229 cells) and
was also higher than in responders (1229 vs 124, P = 0.006) (Table
4). All but two of the non-responders had ED and all became posi-
tive at the time of the second aspirate (P = 0.036) (Tables 3 and 5),
though two patients showed a certain reduction of the degree of
contamination (Figure 2).
Regarding survival, only positive BMA at diagnosis, extensive
disease, positive BMA at re-staging, and lack of response signifi-
cantly affected survival (Table 6). Combining stage of disease and
BMA immunoreactivity at diagnosis, three groups with different
prognosis could be identified: group A, with LD and negative
BMA (ten patients; median survival: 17 months) (‘true LD’);
group B, with LD and positive BMA (seven patients; median
survival: 13 months) (‘untrue LD’); and group C, with ED and
either positive or negative BMA (13 patients; median survival: 9
months). The likelihood of survival was significantly different
between groups: A vs B, P = 0.033; B vs C, P = 0.003; A vs C,
P < 0.001 (Figure 3). In a multivariate analysis, both ED (hazard
ratio = 35.983, P < 0.001) and LD with positive BMA (hazard
ratio = 7.122; P = 0.033) emerged as independent predictors of
poor prognosis (Table 7).
DISCUSSION
Our results can be summarized as follows: (i) BMA contamination
by SCLC cells at diagnosis is related to the extension of disease
and predicts poor survival; (ii) chemotherapy is ineffective in
purging BM from tumour cells; and (iii) the occurrence of tumour
cells in BMA of patients with LD identifies a subgroup of ‘untrue
LD’ patients with reduced life expectation.
This clinicopathological study was mainly aimed at evaluating
the relation between bone marrow involvement and clinical
outcome: by screening 105 mononuclear cells, we have found a
correlation with survival and response to chemotherapy. Therefore
this methodological approach seems acceptable in terms of sensi-
tivity. The screening of a higher number of cells (i.e. 106) requires
immunostaining of many more cytospin slides, and would be
therefore both time-consuming and expensive.
In this study, we found that BMA contamination by tumour cells
at diagnosis is predictive of shorter survival (P = 0.002) (Table 5).
This result, however, could reflect the dismal prognosis of ED
patients, since in our series positive BMA were more frequent in
patients with extensive than limited disease (92.3 vs 41.2% respec-
tively) (P = 0.005). We confirmed also that marrow positivity was
associated with liver metastases, as previously reported (Skov
et al, 1992) (Table 3). This may imply that liver involvement in
patients with positive BMA is more frequent than found with
conventional staging procedures.
Consistently, we detected at least one order of magnitude more
tumour cells in BMA of ED patients (1590 cells) than in those with
conventionally assessed LD (116 cells) (P = 0.008) (Table 4). This
figure is in agreement with previous reports pointing out that the
persistence of residual marrow disease at clinical remission
(Leonard et al, 1990), as well as the presence of tumour cells in
BMA at diagnosis (Bucher et al, 1994; Pasini et al, 1994b, 1995,
1998), are predicitive of early metastatic relapse and reduced
survival rate respectively.
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Table 6 Results of actuarial survival analysis in 30 patients
Variable Category Median P-value
survival








Table 7 Multivariate analysis on the relationship between survival and variables tested in 30 patients
Predictive variables RC SE HR 95% CI P-value
Stage
ED (Group C) 3.583 1032 35.983 4.760–272.007 <0.001
LD/BMA pos (Group B) 1.963 0.921 7.122 1.172–43.286 0.033
(baseline: LD/BMA neg [Group A])
2nd BMA
Positive –0.002 0.963 0.998 0.151–6.601 NS
(baseline: negative)
Disease status
Non-responders –0.810 0.659 0.445 0.122–1.618 NS
(baseline: responders)
Age (median value)
>59 years –0.432 0.508 0.649 0.240–1.757 NS
(baseline: ≤59 years)
Sex
Female 1230 0.756 3420 0.778–15.043 NS
(baseline: male)
RC: regression coefficient; SE: standard error; HR: hazard ratio; 95% CI: confidence intervals.Even more challenging were the data on the relationship of
tumour burden contamination of BMA with the clinical status of
disease or response to chemotherapy. To the best of our knowl-
edge, no study evaluated in sequential aspirates the effects of treat-
ment on BM involvement. Only two reports have briefly alluded to
this issue: in one, earlier systemic relapse occurred in five of eight
patients with immunocytological positive BM at restaging after
chemotherapy (Hay et al, 1988), and in the other, seven patients
with positive pretreatment BMA became negative after induction
chemotherapy (Menard et al, 1988). Moreover, we found a signifi-
cant increase in the number of tumour cells in BMA of patients
with conventionally assessed LD at the time of progression
compared to the baseline contamination. This observation favours
the hypothesis that BM involvement mirrors disease activity at
many other anatomical sites (Leonard et al, 1990) rather than being
a sanctuary for selective and precocious colonization by tumour
cells. However, no variation was detected in non-responsive
patients with ED: this group of patients was not homogeneous,
because 50% of them had stable disease (Table 4). A different type
of non-response to treatment (stabilization or progression) may
perhaps influence the degree of BMA contamination.
In our study, five of the 11 patients (45%) originally negative
became positive, mostly at the time of disease progression (four
patients), reinforcing the concept that bone marrow contamination
parallels the clinical course of the disease. This finding, if con-
firmed in a larger series, may open a new area of investigation: the
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Figure 2 Differences of NCAM-reactive tumour cells between the 1st and the 2nd BMA in 14 responders and ten non-responders to treatment. The former
group had a mean decrease of 652 (s.d. = 2377) tumour cells per patient, whereas the latter group showed a mean increase of 314 (s.d. = 2267) tumour cells
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Figure 3 Survival curves according to three different groups obtained by combining stage of disease and BMA immunoreactivity: group A, with LD and
negative BMA (ten patients; median survival: 17 months) (‘true LD’); group B, with LD and positive BMA (seven patients; median survival: 13 months) (‘untrue
LD’); and group C, with ED and either positive or negative BMA (13 patients; median survival: 9 months). Group A vs group B: P = 0.033; group B vs group C:
P = 0.003; group A vs group C: P < 0.001detection, with repeated sampling of bone marrow, of an increase in
the number of bone marrow tumour cells after chemotherapy might
precociously select patients who are chemoresistant.
As one would expect, the 24 patients, in whom the second BMA
was evaluable also for response to treatment, showed a reduced
number of tumour cells in the bone marrow. In fact, in the second
aspirate we detected a significantly lower contamination in
responders than in non-responders (Table 4 and Figure 2). Among
responders there was a prevalence of patients with limited disease
(10/14) and negative BMA at diagnosis (7/10) (Table 5), and this
is in line with the higher response rates in LD than in ED patients
(Elias, 1997).
Response to treatment, however, was not associated with a
complete clearance of tumour cells in BMA (Table 4). Only two of
the responders became negative (both with short-lasting responses
of 3 months, data not shown), two showed an increased level of
contamination (one patient turning to positive), while the others
remained either positive (four cases) or negative (six cases)
(Figure 2). None of the non-responders became tumour-negative
and all but two showed increased levels of BM contamination
(Figure 2). Assuming a BM volume of 6–7% of the total body
weight, it derives that we detected an initial contamination
approximatively of 107 tumour cells, which decreased to 106
after response to treatment and increased to 108 in patients with
progressive disease.
It has been reported that patients with bone marrow involve-
ment and ED have circulating tumour cells under steady-state
conditions and also tumour cell recruitment upon mobilization of
peripheral blood progenitor cells (Ross et al, 1993; Brugger et al,
1994). Our data do not confirm the efficacy of chemotherapy as a
method for ‘in vivo’ purging the bone marrow. In the clinical
setting, there is a growing consensus about the use of standard
chemotherapy for both tumour debulking and bone marrow
purging before high-dose chemotherapy (Brugger et al, 1994;
Elias, 1997). In order to verify this hypothesis, two cooperative
ongoing trials on high-dose chemotherapy in SCLC (Random-
ICE, conducted by the EMBT group and the phase II trial CALGB
9331/SWOG 9433) have introduced the evaluation of contamina-
tion before and after standard chemotherapy. However, according
to our results, chemotherapy is ineffective in purging bone
marrow, even in responsive patients who were mostly LD. In fact a
residual marrow tumour mass of about 106 cells still persists after
treatment. Therefore, these data support the use of further manipu-
lation of bone marrow or peripheral blood progenitor cell products
(i.e. ‘ex vivo’ purging, selection of CD34+ cells), in order to
ensure a further reduction of contaminating tumour cells.
Interestingly, tumour cells were also detected in 7/17 LD
patients (41.2%). This finding confirms immunocytochemistry as
a more sensitive procedure in assessing BM for malignant cells in
SCLC patients. In fact, also previous studies reported that 30–50%
of LD patients had BMA contamination when evaluated immuno-
cytochemically (Berendsen et al, 1988; Hay et al, 1988; Moss et al,
1988; Trillet et al, 1989; Beiske et al, 1992; Pasini et al, 1994b,
1995, 1998). The amount of marrow involvement of these ‘untrue
LD’ patients was apparently lower than that of ED patients, though
this did not achieve statistical significance. This finding is in
agreement with the median survival of these patients which was
intermediate between ‘true LD’ and ED patients (Figure 3). These
results were also substantiated by a multivariate analysis where
BMA positivity in patients with LD emerged as an independent
factor of prognosis (Table 6). This is the first report documenting
the existence of a subset of SCLC patients with intermediate
survival substantiated by a multivariate analysis. Therefore, we
suggest that the search for tumour cells in BMA by immunocyto-
chemistry may be an easy and reproducible method for identifying
subsets of patients with LD at better prognosis. These patients with
‘true LD’ (i.e. with absence of immunoreactive tumour cells in
BMA) may be suitable for novel therapeutic strategies, including
high-dose chemotherapy, immunotherapy and targeted immuno-
therapy (Myklebust et al, 1993a, 1993b). Further studies are in
progress in our laboratory to confirm the role of immunocyto-
chemistry of bone marrow among the prognostic factors already
identified in large studies of SCLC patients.
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